Site Under Construction

Relapse rate among smear-positive leprosy cases after 12 blister packs and 24 blister packs of multibacillary drug therapy in a tertiary hospital

Christine Marie N. Chia-Acosta, MD, FPDS, Ricky Hipolito, MD, FPDS, Ma. Teresita G. Gabriel, MD, FPDS, Emmerson Gale S. Vista, MD, FPDS, Grace C. Manuel, RMT

Abstract

Background

Several trials on relapse rates on duration of multibacillary regimens have varying results.

Objective

To compare the relapse rate among smear-positive Leprosy patients receiving 12 blister packs of multibacillary drug therapy and 24 blister packs of multibacillary drug therapy.

Method

A review of records of smear positive Leprosy patients seen from 2002 to 2006 was done. Demographic, clinical and therapeutic data were collected. Bacteriologic index was determined from Leprosy Laboratory records.

Results

A total of 391 patients were found to have complete records for review and analysis. Relapse rate was 11.9%(28) for patients who received 12 blister packs and 1.91%(3) for patients who received 24 blister packs and the difference was found to be statistically significant (p<0.01). Distribution of relapse was statistically significant according to age (p<0.01), bacteriologic index (p<0.01) and clinical spectrum (p<0.01).

Conclusion

Relapse rates shown among smear positive leprosy patients receiving 12 blister packs vs. those receiving 24 blister packs was statistically higher which differs from previously published studies. Significant predictors were clinical spectrum, bacteriologic index of >3.5, and >4 and number of blister packs.

References

Department of Health and Families. Guidelines for the Control of Leprosy in the Northern Territory, 3rd ed; 2010.1-58
Rea T, Modlin R. Leprosy. Fitzpatrick’s Dermatology in General Medicine. 2009; 186:1786.
World Health Organization. Weekly Epidemiological record. 2011; 36: 389-400.
Sehgal V, Joginder. Slit Skin Smear in Leprosy. Int J Derm. 1990; 29(1): 9-15.
Bandit C. Recent Advances in Leprosy Chemotherapy. J Trop Med Parasitol. 2006; 29:68-76.
World Health Organization. Guidelines for the Global Surveillance of Drug Resistance. SEA-GLP. 2009; 2: 1-32.
World Health Organization. Guidelines for Global Surveillance of Drug Resistance in Leprosy. 2009: 6.
The leprosy unit, WHO. Risk of relapse in leprosy. India J Lepr. 1995; 67:13-26.
World Health Organization. Chemotherapy of Leprosy. WHO Tech Rep Ser 847:1, 1994
Mitranna P, Marne RB, Varikkodan R, Bala N, Dandakeri S, Martis J. Relapses In multibacillary leprosy patients after Multidrug therapy. Lepr Rev. 2008; 79: 320-324.
Maghanoy A, Mallari I, Balagon M, Saunderson P. Relapse study in smear-positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines. Lepr Rev. 2011; 82: 65-69.
Aveillera, JC, Vianna FR, Boechat AM, Alves LM, Madeira S. Persistence of viable bacilli in highly bacilliferous multibacillary leprosy patients after twelve doses of multidrug therapy WHO/MDT. Hansen Int. 2003; 28(1): 49-52.
Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five group system. Int J Leprosy. 1966; 34: 255–273.
Cellona RV. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Lepr other Mycobact Dis. 2003;71: 308-319.

Efficacy and safety of turmeric 1% emollient cream in the control of chronic kidney disease-associated pruritus in hemodialysis patients: A randomized double-blind clinical trial

Relapse rate among smear-positive leprosy cases after 12 blister packs and 24 blister packs of multibacillary drug therapy in a tertiary hospital

Christine Marie N. Chia-Acosta, MD, FPDS, Ricky Hipolito, MD, FPDS, Ma. Teresita G. Gabriel, MD, FPDS, Emmerson Gale S. Vista, MD, FPDS, Grace C. Manuel, RMT

Abstract

References

Efficacy and safety of turmeric 1% emollient cream in the control of chronic kidney disease-associated pruritus in hemodialysis patients: A randomized double-blind clinical trial

Basal cell nevus syndrome in a 48-year-old Filipino

Topical sirolimus for the treatment of angiofi bromas in a child with tuberous sclerosis complex: fi rst reported case in the Philippines

REquesting Permission

Relapse rate among smear-positive leprosy cases after 12 blister packs and 24 blister packs of multibacillary drug therapy in a tertiary hospital